Product Description
The research-grade biosimilar is a recombinant antibody to Anetumab without the drug conjugation. The original antibody-drug conjugate (Anetumab Ravtansine) consists of an anti-mesothelin (MSLN) human IgG1 antibody conjugated to DM4, an anti-tumor chemical derivative of maytansine via a disulfide-containing cleavable sulfo-SPDB linker. Upon interaction and internalization by MSLN expressing tumor cells, the DM4 is detached from the antibody due to proteolytic cleavage. The DM4 then inhibits polymerization of the tubulin and disrupts the microtubule assembly, thereby leading to cell cycle arrest and apoptosis. The original antibody-drug conjugate is used as an investigational agent to treat pancreatic, ovarian cancer, and advanced or recurrent mesothelioma.
Biovision | A2272 | Anti-MSLN (Anetumab), Human IgG1 Antibody DataSheet
Antibody Target: MSLN
Target Alternative Name: MPF, SMRP, MSLN, Mesothelin, CAK1, CAK1 Antigen
Tag Line: The biosimilar is a human IgG1 antibody that targets Mesothelin (MSLN)
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, lambda
Species Reactivities: Human
Immunogen Sequence: Human MSLN
Accession #: DB14809
Gene ID: 10232
Appearance: Colorless liquid
Form: Liquid
Concentration:
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE